A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

NCT04856787 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment of the Company's R\&D Strategy

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: SHR-1701、 BP102 、XELOX
DRUG: SHR-1701、 BP102 、XELOX
DRUG: placebo、 BP102、 XELOX

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.